Stock listing
Hanover:19X Axsome Therapeutics, Inc. Aktie
German listing (Hanover) of Axsome Therapeutics, Inc. · home listing NASDAQ:AXSM
Follow Axsome Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AXSM
$129.36 USD -4.64 (-3.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AXSM
- Day range
- $128.24 – $135.09 USDNov 20, 2026
- Volume
- 811,750 sharesNov 20, 2026
- Market cap
- $6.80B USDAt the close on Nov 20, 2026 · price × 52.60M shares outstanding
- 52-week range
- $123.00 – $260.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $144.6M USDMedian day 802,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AXSM · Home | $129.36 USD | -4.64 (-3.5%) | 811,750 | $134.00 | $135.09 | $128.24 | $134.00 | Close on Nov 20, 2026 |
| LSE:0HKF | $130.15 USD | -5.05 (-3.7%) | 841 | $134.70 | $137.10 | $130.15 | $135.20 | Close on Nov 20, 2026 |
| Frankfurt:19X | €118.00 EUR | -4.15 (-3.4%) | — | €121.35 | €121.35 | €118.00 | €122.15 | Close on Nov 20, 2026 |
| Stuttgart:19X | €117.20 EUR | -6.35 (-5.1%) | — | €122.40 | €123.35 | €116.85 | €123.55 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AXSM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $129.36 | -4.64 | -3.5% | $134.00 | $135.09 | $128.24 | 811,750 | |
| $134.00 | -1.95 | -1.4% | $135.65 | $136.62 | $131.56 | 743,387 | |
| $135.95 | -1.06 | -0.8% | $136.36 | $137.46 | $134.67 | 518,111 | |
| $137.01 | -4.68 | -3.3% | $141.25 | $141.70 | $136.33 | 989,131 | |
| $141.69 | -2.68 | -1.9% | $143.99 | $145.29 | $136.63 | 972,538 | |
| $144.37 | -4.87 | -3.3% | $148.07 | $150.34 | $144.01 | 979,492 | |
| $149.24 | +8.27 | +5.9% | $141.41 | $151.31 | $141.41 | 1,072,464 | |
| $140.97 | +7.01 | +5.2% | $134.60 | $142.93 | $133.87 | 1,285,565 | |
| $133.96 | +1.59 | +1.2% | $133.29 | $134.71 | $131.41 | 1,117,926 | |
| $132.37 | +2.57 | +2.0% | $130.46 | $133.79 | $130.00 | 718,345 | |
| $129.80 | -7.20 | -5.3% | $137.00 | $137.56 | $128.99 | 1,109,346 | |
| $137.00 | -2.61 | -1.9% | $140.56 | $140.56 | $134.38 | 1,034,191 | |
| $139.61 | +3.60 | +2.6% | $136.88 | $145.50 | $136.88 | 1,679,392 | |
| $136.01 | -8.42 | -5.8% | $136.50 | $138.03 | $123.00 | 2,716,703 | |
| $144.43 | +0.98 | +0.7% | $143.23 | $146.17 | $131.27 | 2,090,305 | |
| $143.45 | -0.06 | 0.0% | $146.06 | $147.49 | $140.42 | 850,317 | |
| $143.51 | +1.31 | +0.9% | $141.60 | $144.14 | $140.49 | 738,719 | |
| $142.20 | -1.86 | -1.3% | $143.99 | $145.44 | $141.15 | 1,104,340 | |
| $144.06 | -0.98 | -0.7% | $145.29 | $145.34 | $142.00 | 884,118 | |
| $145.04 | -11.03 | -7.1% | $154.66 | $154.74 | $143.90 | 1,593,141 | |
| $156.07 | -0.24 | -0.2% | $156.13 | $158.08 | $154.24 | 832,350 | |
| $156.31 | -3.27 | -2.0% | $158.83 | $160.82 | $156.04 | 524,795 | |
| $159.58 | +3.77 | +2.4% | $157.65 | $164.79 | $157.38 | 653,892 | |
| $155.81 | -1.33 | -0.8% | $157.54 | $158.66 | $154.50 | 781,732 | |
| $157.14 | -4.65 | -2.9% | $160.43 | $160.43 | $156.09 | 873,100 | |
| $161.79 | -0.43 | -0.3% | $163.44 | $169.96 | $160.27 | 802,600 | |
| $162.22 | +5.90 | +3.8% | $156.44 | $164.00 | $155.18 | 893,200 | |
| $156.32 | -9.68 | -5.8% | $166.01 | $166.55 | $155.69 | 1,328,600 | |
| $166.00 | -2.35 | -1.4% | $169.50 | $170.80 | $165.02 | 663,000 | |
| $168.35 | -1.73 | -1.0% | $170.18 | $170.64 | $166.12 | 894,500 | |
| $170.08 | -2.89 | -1.7% | $170.09 | $172.28 | $166.21 | 1,073,600 | |
| $172.97 | -1.37 | -0.8% | $174.00 | $177.91 | $172.48 | 887,300 | |
| $174.34 | -2.74 | -1.5% | $176.52 | $176.52 | $169.30 | 1,367,800 | |
| $177.08 | -2.17 | -1.2% | $179.25 | $179.70 | $175.73 | 858,900 | |
| $179.25 | -2.82 | -1.5% | $182.55 | $182.55 | $175.46 | 981,400 | |
| $182.07 | -2.32 | -1.3% | $184.39 | $185.67 | $181.75 | 660,200 | |
| $184.39 | -1.75 | -0.9% | $186.51 | $188.00 | $184.00 | 1,033,900 | |
| $186.14 | -7.75 | -4.0% | $191.41 | $194.25 | $182.10 | 1,577,600 | |
| $193.89 | -1.20 | -0.6% | $194.98 | $198.96 | $193.11 | 707,400 | |
| $195.09 | -0.94 | -0.5% | $197.68 | $201.42 | $194.35 | 838,200 | |
| $196.03 | +2.58 | +1.3% | $193.02 | $197.11 | $190.72 | 386,100 | |
| $193.45 | -9.65 | -4.8% | $204.01 | $204.70 | $189.05 | 913,000 | |
| $203.10 | -2.39 | -1.2% | $205.68 | $207.01 | $202.52 | 299,800 | |
| $205.49 | -2.29 | -1.1% | $208.17 | $210.85 | $203.38 | 543,500 | |
| $207.78 | -6.50 | -3.0% | $212.05 | $213.27 | $206.92 | 869,300 | |
| $214.28 | +2.31 | +1.1% | $215.59 | $216.47 | $208.63 | 681,400 | |
| $211.97 | +7.90 | +3.9% | $202.95 | $214.64 | $201.94 | 644,900 | |
| $204.07 | -12.51 | -5.8% | $215.02 | $215.02 | $203.78 | 591,300 | |
| $216.58 | -4.17 | -1.9% | $221.93 | $223.29 | $216.00 | 718,800 | |
| $220.75 | +9.635 | +4.6% | $212.71 | $229.62 | $212.44 | 1,228,400 | |
| $211.12 | +0.485 | +0.2% | $210.63 | $211.65 | $208.01 | 526,400 | |
| $210.63 | +2.81 | +1.4% | $207.97 | $211.22 | $205.76 | 428,400 | |
| $207.82 | +1.14 | +0.6% | $205.00 | $210.86 | $202.00 | 385,800 | |
| $206.68 | -1.67 | -0.8% | $207.01 | $208.51 | $205.49 | 438,200 | |
| $208.35 | -1.57 | -0.7% | $209.32 | $210.59 | $206.60 | 558,800 | |
| $209.92 | +7.09 | +3.5% | $203.11 | $210.55 | $201.55 | 608,200 | |
| $202.83 | +4.31 | +2.2% | $199.71 | $205.94 | $199.71 | 656,300 | |
| $198.52 | -0.50 | -0.3% | $199.00 | $200.74 | $197.05 | 503,700 | |
| $199.02 | -7.25 | -3.5% | $205.70 | $205.70 | $199.00 | 441,200 | |
| $206.27 | -0.88 | -0.4% | $205.00 | $208.26 | $203.71 | 586,300 | |
| $207.15 | +1.67 | +0.8% | $204.48 | $210.68 | $203.70 | 378,400 | |
| $205.48 | +0.08 | 0.0% | $207.58 | $209.53 | $200.19 | 731,500 | |
| $205.40 | -2.37 | -1.1% | $207.00 | $208.09 | $205.09 | 293,200 | |
| $207.77 | -0.26 | -0.1% | $207.22 | $210.87 | $206.50 | 734,900 | |
| $208.03 | -10.17 | -4.7% | $216.50 | $217.85 | $206.26 | 620,900 |
- Ticker
- Hanover:19X
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 2, 2026
Axsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 50 slides
Latest news
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Nov 19, 2026
Closed $129.36 (-3.5%) on Nov 20, 2026
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 2, 2026
Closed $136.01 (-5.8%) on Nov 2, 2026
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Oct 7, 2026
Closed $172.97 (-0.8%) on Oct 7, 2026
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
Sep 21, 2026
Closed $205.49 (-1.1%) on Sep 21, 2026
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Sep 17, 2026
Closed $214.28 (+1.1%) on Sep 17, 2026
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Aug 31, 2026
Closed $198.52 (-0.3%) on Aug 31, 2026
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 10, 2026
Closed $220.89 (+3.8%) on Aug 10, 2026
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Jul 15, 2026
Closed $237.53 (+1.0%) on Jul 15, 2026
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
Jul 14, 2026
Closed $235.26 (+3.1%) on Jul 14, 2026
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Jul 7, 2026
Closed $249.76 (+3.0%) on Jul 7, 2026
Axsome Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 230 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 2, 2026
- Decks
- 48 decks · latest November 2026
Where Axsome Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AXSM · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2AA7B | LS Exchange | Germany | EUR |
| Tradegate:19X | Tradegate | Germany | EUR |
| gettex:19X | gettex | Germany | EUR |
| BMV:AXSM | BMV | Mexico | MXN |
| LSE:0HKF | LSE | United Kingdom | USD |
| Lang & Schwarz:A2AA7B | Lang & Schwarz | Germany | EUR |
| Milan:1AXSM | Milan | Italy | EUR |
| Frankfurt:19X | Frankfurt | Germany | EUR |
| BIVA:AXSM | BIVA | Mexico | MXN |
| BOATS:AXSM | BOATS | United States | USD |
| BX Swiss:AXSM | BX Swiss | Switzerland | CHF |
| Stuttgart:19X | Stuttgart | Germany | EUR |
| Dusseldorf:19X | Dusseldorf | Germany | EUR |
| Hamburg:19X | Hamburg | Germany | EUR |
| Munich:19X | Munich | Germany | EUR |
| Hanover:19X · This page | Hanover | Germany | EUR |
| Xetra:19X | Xetra | Germany | EUR |
Valuation
EV/sales 7.7× against a median of 56.2×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.68B USD
- P/E
- Loss
- EV/sales
- 7.7×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 64.5×
- Gross margin
- Not reported
- Operating margin
- −17.4%
- Net margin
- −18.2%
- Debt to equity
- 1.8×
- Beta vs S&P 500
- 0.69
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Alkermes plc · NASDAQ:ALKS | US$7.55B | US$8.31B | n/a | 4.7× | 57.3× | 4.0× | −0.0% | 0.8× | 0.80 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Median of the others | US$6.54B | US$6.07B | 56.2× | 57.3× | 8.6× | −322.1% | 0.3× | 1.12 |
Forecasts
18 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 264.62 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.46 · 13 analysts
- Revenue, year to Dec 2026
- 954.3M · 21 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Herriot Tabuteau | CHIEF EXECUTIVE OFFICER |
| Nick Pizzie | CHIEF FINANCIAL OFFICER |
| Mark Jacobson | CHIEF OPERATING OFFICER |
| Hunter Murdock | GENERAL COUNSEL |
| Ashley Dong | Senior Director, Investor Relations |
| Darren Opland | Senior Director, Corporate Communications |
| Ari Maizel | CHIEF COMMERCIAL OFFICER |
Board
| Director | Role |
|---|---|
| Herriot Tabuteau | CHIEF EXECUTIVE OFFICER |
| Mark Coleman | DIRECTOR |
| Mark Saad | DIRECTOR |
| Roger Jeffs | DIRECTOR |
| Susan Mahony | DIRECTOR |
Events
Calls
| Call | When | Status |
|---|---|---|
| Axsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call | Mon, Nov 02, 2026 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call | Mon, Aug 10, 2026 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q1 2026 Earnings Call | Mon, May 04, 2026 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q4 2025 Earnings Call | Mon, Feb 23, 2026 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q2 2025 Earnings Call | Mon, Aug 04, 2025 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q4 2024 Earnings Call | Mon, Jan 13, 2025 · 1:00 PM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:00 AM ET | Replay |
| Axsome Therapeutics (NASDAQ:AXSM) Q2 2024 Earnings Call | Mon, Aug 05, 2024 · 8:00 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · Before open | −5.8% |
| Q2 2026 | Aug 10, 2026 · Before open | +3.8% |
| Q1 2026 | May 4, 2026 · Before open | +8.3% |
| Q4 2025 | Feb 23, 2026 | −7.5% |
| Q3 2025 | Nov 3, 2025 · Before open | +0.6% |
| Q2 2025 | Aug 4, 2025 · Before open | +3.4% |
| Q1 2025 | May 5, 2025 · Before open | +3.8% |
| Q4 2024 | Feb 18, 2025 · Before open | −2.3% |
| Q3 2024 | Nov 12, 2024 · Before open | +9.3% |
| Q2 2024 | Aug 5, 2024 · Before open | −1.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · Before open | +1.5% |
| Q4 2023 | Feb 20, 2024 · Before open | −12.6% |
| Q3 2023 | Nov 6, 2023 · Before open | −4.2% |
| Q2 2023 | Aug 7, 2023 · Before open | −3.5% |
| Q1 2023 | May 8, 2023 · Before open | +5.4% |
| Q4 2022 | Feb 27, 2023 · Before open | +5.0% |
| Q3 2022 | Nov 7, 2022 · Before open | −0.5% |
| Q2 2022 | Aug 9, 2022 · Before open | +3.4% |
| Q1 2022 | May 2, 2022 · Before open | +7.2% |
| Q4 2021 | Mar 1, 2022 · Before open | +10.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 50 slides | November 2026 |
| Q2 2026 Earnings Presentation | Earnings | 46 slides | Aug 10, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 49 slides | May 4, 2026 |
| Investor Presentation (May 2026) | Investor deck | 26 slides | May 1, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 47 slides | Feb 23, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 46 slides | Nov 3, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 45 slides | Aug 4, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 26 slides | May 6, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 45 slides | May 5, 2025 |
| FY2024 Earnings Presentation | Earnings | 46 slides | Feb 18, 2025 |
All 48 decks
Financings
| Raise | Date |
|---|---|
| Strategic investment of common stock Closed: US$15M raised · US$107.14 a share Buyers: Blackstone ($15 million of Axsome common stock) | May 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$9.00 a share on Nov 19, 2015.
- Price
- US$9.00 a share
- Shares offered
- 5,666,667 shares of common stock
- Offering size
- US$51 million
- Underwriters' option
- Up to 850,000 more shares
- Listing
- AXSM on the Nasdaq Capital Market
- Underwriters
- Ladenburg Thalmann, Cantor Fitzgerald & Co., Brean Capital · In the order on the cover
- Shares delivered
- On or about Nov 24, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 25, 2015 |
| Filed publicly | Oct 13, 2015 |
| Amended once | Nov 2, 2015 |
| Shares registered with an exchange | Nov 16, 2015 |
| Declared effective by the SEC | Nov 19, 2015 |
| Final prospectus, with the price | Nov 19, 2015 |
Filings
| Filing | Filed |
|---|---|
| EFFECT · Notice that a registration is effective | Nov 19, 2015 |
| 424B4 · Prospectus | Nov 19, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Nov 17, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 16, 2015 |
| CORRESP · Letter to the SEC | Nov 16, 2015 |
| CORRESP · Letter to the SEC | Nov 16, 2015 |
| S-1/A · Registration statement, amended | Nov 2, 2015 |
| CORRESP · Letter to the SEC | Oct 29, 2015 |
| S-1 · Registration statement | Oct 13, 2015 |
| CORRESP · Letter to the SEC | Oct 13, 2015 |
All 12 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 22, 2015 |
| DRS · Draft registration statement | Aug 25, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 19, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.5M | 385.7M | 270.6M | 0 | ||||||
| Cost of revenue | 5.20M | |||||||||
| Gross profit | -5.20M | |||||||||
| Research and development | 183.3M | 187.1M | 97.9M | 57.9M | 58.1M | 70.2M | 53.6M | 23.5M | 20.0M | 21.2M |
| Selling, general and administrative | 570.6M | 411.4M | 323.1M | 159.3M | 66.6M | 28.9M | ||||
| Operating income | -166.8M | -280.6M | -231.8M | -179.8M | -124.7M | -99.1M | -67.2M | -32.8M | -27.2M | -27.5M |
| Depreciation and amortization | 503.0K | 532.0K | 459.0K | 263.0K | 76.0K | 23.9K | 37.3K | 48.9K | 42.6K | 20.5K |
| EBITDA | -166.3M | -280.0M | -231.4M | -179.5M | -124.6M | -99.1M | -67.2M | -32.8M | -27.1M | -27.5M |
| Interest expense | -15.9M | -21.6M | -20.0M | -9.66M | ||||||
| Income before tax | -183.7M | -287.1M | -238.3M | -187.1M | -130.4M | |||||
| Income tax | -530.0K | 85.0K | 960.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -183.2M | -287.2M | -239.2M | -187.1M | -130.4M | -102.9M | -68.3M | -31.0M | -28.9M | -27.2M |
| Earnings per share, basic | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | -1.15 | -1.27 | -1.42 |
| Earnings per share, diluted | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | -1.15 | -1.27 | -1.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 322.9M | 315.4M | 386.2M | 200.8M | 86.5M | 183.9M | 220.0M | 14.0M | 34.0M | 36.6M |
| Receivables | 224.5M | 142.0M | 94.8M | 37.7M | ||||||
| Inventory | 27.9M | 15.7M | 15.1M | 4.32M | ||||||
| Current assets | 589.0M | 485.1M | 504.3M | 245.6M | 86.5M | 184.0M | 220.4M | 15.2M | 35.3M | 38.0M |
| Property, plant and equipment | 562.0K | 584.0K | 846.0K | 722.0K | 283.8K | 52.6K | 30.6K | 51.8K | 68.1K | 100.7K |
| Goodwill | 12.0M | 12.0M | 12.0M | 10.3M | ||||||
| Total assets | 689.8M | 568.5M | 588.2M | 331.5M | 87.8M | 186.1M | 220.5M | 15.4M | 35.6M | 38.2M |
| Accounts payable | 65.5M | 72.0M | 40.7M | 38.6M | 13.1M | 13.5M | 10.9M | 3.69M | 3.44M | 4.08M |
| Current liabilities | 378.8M | 230.1M | 138.9M | 96.6M | 23.1M | 23.4M | 24.5M | 10.8M | 12.2M | 7.17M |
| Long-term debt | 117.7M | 180.7M | 178.1M | 94.3M | 49.1M | 48.3M | 17.3M | 3.62M | 6.66M | 9.47M |
| Total debt | 187.7M | 180.7M | 178.1M | 94.3M | 49.1M | 48.3M | 19.9M | 6.91M | 9.93M | 9.74M |
| Total liabilities | 601.5M | 511.5M | 397.3M | 221.9M | 72.2M | 72.3M | 41.8M | 14.4M | 18.8M | 16.6M |
| Shareholders' equity | 88.3M | 57.0M | 191.0M | 109.6M | 15.6M | 113.8M | 178.7M | 937.9K | 16.7M | 21.6M |
| Shares outstanding | 50.9M | 48.7M | 47.4M | 43.5M | 37.8M | 37.4M | 36.9M | 30.1M | 25.5M | 19.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -93.4M | -128.4M | -145.1M | -116.5M | -108.2M | -78.5M | -46.4M | -30.1M | -26.5M | -21.3M |
| Capital spending | -480.0K | -270.0K | -582.0K | -702.0K | -308.0K | -45.9K | -16.1K | -32.7K | -9.90K | -104.6K |
| Free cash flow | -93.9M | -128.7M | -145.7M | -117.2M | -108.5M | -78.5M | -46.4M | -30.1M | -26.5M | -21.4M |
| Cash from investing | -480.0K | -270.0K | -582.0K | -53.7M | -308.0K | -45.9K | -16.1K | -32.7K | -9.90K | -104.6K |
| Cash from financing | 101.5M | 57.8M | 331.0M | 284.6M | 11.1M | 42.4M | 252.4M | 10.0M | 23.9M | 9.97M |
| Change in cash | 7.58M | -70.8M | 185.4M | 114.4M | -97.4M | -36.1M | 206.0M | -20.1M | -2.60M | -11.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 23, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 31, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 31, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Nov 3, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2025 | Current report | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 27, 2025 | Other filings | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 18, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 18, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2024 | Current report | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| 8-K · Current report | Aug 21, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 9, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
This page holds 200 of 672 filings. Open Filings
Cap table
Built by 6ix from Axsome Therapeutics, Inc.’s releases · as of Oct 26, 2026
- Common shares
- 52,599,985
- Fully diluted
- 52,599,985
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 52,599,985 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 52,599,985 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Myrtle S Potter Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Immunovant, Inc. (Director · Dec 18, 2019 – Dec 18, 2019 · Past); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Insmed Incorporated (Director · Dec 11, 2014 – May 15, 2018 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past) | Director · Jun 16, 2017 – Jun 7, 2019 · Past |
| Roger Jeffs Other companies: Liquidia Corporation (Chief Executive Officer · Since at least Nov 18, 2020); Sio Gene Therapies Inc (Director · Feb 8, 2018 – Apr 15, 2019 · Past); Albireo Pharma Inc (Director · Sep 27, 2017 – Jun 24, 2021 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 26, 2017 – Sep 7, 2018 · Past); United Therapeutics Corporation (President & Co-CEO, Director · Jan 5, 2006 – Mar 15, 2016 · Past) | DIRECTOR · Since at least Nov 19, 2015 |
| Susan Mahony Other companies: Zymeworks Inc. (Director · Since at least Jun 3, 2019); Assembly Biosciences, Inc. (Director · Since at least Dec 14, 2017); Eli Lilly and Company (SVP & Pres., Lilly Oncology · Jul 28, 2015 – Apr 13, 2018 · Past) | DIRECTOR · Since at least Oct 10, 2023 |
| David C Marek Other companies: Myovant Sciences Ltd (Principal Executive Officer, Director · Jan 4, 2021 – Mar 10, 2023 · Past); WebMD Health Corp (Executive Vice President · Sep 4, 2012 – Sep 4, 2013 · Past) | Chief Commercial Officer · Sep 4, 2019 – Mar 17, 2020 · Past |
| John Golubieski Other companies: BioDelivery Sciences International Inc (See Remarks · Oct 25, 2021 – Mar 22, 2022 · Past) | Chief Financial Officer · Aug 4, 2017 – Aug 4, 2017 · Past |
| ari Maizel | CHIEF COMMERCIAL OFFICER · Since at least Oct 14, 2024 |
| Ashley Dong | Senior Director, Investor Relations · Since at least Nov 3, 2026 |
| Darren Opland | Senior Director, Corporate Communications · Since at least Nov 3, 2026 |
| Herriot Tabuteau | Chief Executive Officer, Director · Since at least Sep 12, 2025 |
| Hunter Murdock | GENERAL COUNSEL · Since at least Jun 13, 2022 |
All 15 people
| Person | Seat |
|---|---|
| Mark Coleman | DIRECTOR · Since at least Nov 19, 2015 |
| Mark Jacobson | CHIEF OPERATING OFFICER · Since at least May 27, 2025 |
| Mark Saad | Director · Since at least Jun 8, 2026 |
| Nick Pizzie | CHIEF FINANCIAL OFFICER · Since at least Jun 9, 2026 |
| Nick Pizzie | Chief Financial Officer · Since at least Jan 22, 2026 |
Log in to ask 6ix AI your own questions about Axsome Therapeutics, Inc.